AR097932A1 - Antagonista del receptor de somatostatina del subtipo 5 (sstr5) - Google Patents

Antagonista del receptor de somatostatina del subtipo 5 (sstr5)

Info

Publication number
AR097932A1
AR097932A1 ARP140103713A ARP140103713A AR097932A1 AR 097932 A1 AR097932 A1 AR 097932A1 AR P140103713 A ARP140103713 A AR P140103713A AR P140103713 A ARP140103713 A AR P140103713A AR 097932 A1 AR097932 A1 AR 097932A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
compound
ring
alkyl group
salt
Prior art date
Application number
ARP140103713A
Other languages
English (en)
Inventor
hirose Hideki
Yamasaki Takeshi
Nishikawa Yoichi
Yamashita Tohru
Kina Asato
Kasai Shizuo
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR097932A1 publication Critical patent/AR097932A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un compuesto que tiene una acción antagonista del SSTR5 y el uso del compuesto como medicamento. que comprende el compuesto o una sal de él, y el uso del compuesto o una sal de él como agente para la profilaxis o el tratamiento de la diabetes mellitus. Reivindicación 1: Un compuesto representado por la fórmula (1), caracterizado porque el anillo P representa un anillo heterocíclico aromático de 6 miembros; el anillo A representa un anillo heterocíclico saturado que contiene nitrógeno de 4 a 7 miembros opcionalmente sustituido; el anillo B representa un anillo de benceno opcionalmente sustituido o un anillo heterocíclico opcionalmente sustituido; R¹ y R² representan cada uno de forma independiente un átomo de hidrógeno, un grupo C₁₋₆ alquilo opcionalmente sustituido, un grupo C₃₋₁₀ cicloalquilo o CO₂R (en donde R representa un átomo de hidrógeno o un grupo C₁₋₆ alquilo opcionalmente sustituido); uno de R¹ y R² es CO₂R; W representa un grupo C₁₋₂ alquileno opcionalmente sustituido con un grupo C₁₋₆ alquilo; y R³, R⁴, R⁵ y R⁶ representan cada uno de forma independiente un átomo de hidrógeno o un grupo C₁₋₆ alquilo; o una sal de él.
ARP140103713A 2013-10-07 2014-10-06 Antagonista del receptor de somatostatina del subtipo 5 (sstr5) AR097932A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013209826 2013-10-07

Publications (1)

Publication Number Publication Date
AR097932A1 true AR097932A1 (es) 2016-04-20

Family

ID=51842719

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103713A AR097932A1 (es) 2013-10-07 2014-10-06 Antagonista del receptor de somatostatina del subtipo 5 (sstr5)

Country Status (23)

Country Link
US (2) US9353108B2 (es)
EP (1) EP3055309B1 (es)
JP (1) JP6411520B2 (es)
CN (1) CN105612158B (es)
AR (1) AR097932A1 (es)
BR (1) BR112016007620B1 (es)
CA (1) CA2926544C (es)
CY (1) CY1121163T1 (es)
DK (1) DK3055309T3 (es)
ES (1) ES2687102T3 (es)
HR (1) HRP20181372T1 (es)
HU (1) HUE039386T2 (es)
JO (1) JO3442B1 (es)
LT (1) LT3055309T (es)
PL (1) PL3055309T3 (es)
PT (1) PT3055309T (es)
RS (1) RS57743B1 (es)
RU (1) RU2671958C2 (es)
SI (1) SI3055309T1 (es)
TR (1) TR201810506T4 (es)
TW (1) TWI648276B (es)
UY (1) UY35774A (es)
WO (1) WO2015052910A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605000B2 (en) * 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
CN107001332B (zh) * 2014-12-02 2020-05-15 豪夫迈·罗氏有限公司 哌啶衍生物
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202207929A (zh) * 2020-05-13 2022-03-01 日商思可海雅藥品股份有限公司 膽道系疾病的診斷輔助、預防或治療劑
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116354961A (zh) * 2021-12-27 2023-06-30 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
ES2252524T3 (es) 2001-09-24 2006-05-16 Bayer Pharmaceuticals Corporation Preparacion y uso de derivados de 1,5,6,7-tetrahidropirrolo(3,2-c)piridina para el tratamiento de la obesidad.
RU2004112787A (ru) * 2001-09-26 2005-10-10 Байер Фармасьютикалс Корпорейшн (US) Производные 1,6-нафтиридина как противодиабетические средства
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2004039365A1 (en) 2002-11-01 2004-05-13 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
US20050101644A1 (en) 2003-11-10 2005-05-12 Schering Aktiengesellschaft Benzylether amine compounds useful as CCR-5 antagonists
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP2431367A3 (en) 2006-06-27 2012-07-04 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
WO2008019967A2 (en) 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives
WO2008047821A1 (fr) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
GEP20115241B (en) 2006-10-19 2011-06-10 Takeda Pharmaceutical Indole compound
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
TW200838515A (en) 2007-02-09 2008-10-01 Takeda Pharmaceutical Fused ring compound
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
CA2759651A1 (en) 2009-05-07 2010-11-11 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
US8742110B2 (en) 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
CA2818050A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
AR098215A1 (es) 2013-10-29 2016-05-18 Takeda Pharmaceuticals Co Compuesto heterocíclico

Also Published As

Publication number Publication date
HRP20181372T1 (hr) 2018-10-19
PL3055309T3 (pl) 2018-10-31
US20160237087A1 (en) 2016-08-18
RU2016117732A (ru) 2017-11-15
WO2015052910A1 (en) 2015-04-16
BR112016007620B1 (pt) 2020-05-26
RS57743B1 (sr) 2018-12-31
TW201536784A (zh) 2015-10-01
RU2671958C2 (ru) 2018-11-08
EP3055309B1 (en) 2018-06-13
ES2687102T3 (es) 2018-10-23
CN105612158A (zh) 2016-05-25
DK3055309T3 (en) 2018-08-27
US9353108B2 (en) 2016-05-31
LT3055309T (lt) 2018-08-27
HUE039386T2 (hu) 2018-12-28
TR201810506T4 (tr) 2018-08-27
CN105612158B (zh) 2017-06-30
CA2926544A1 (en) 2015-04-16
TWI648276B (zh) 2019-01-21
JP2016531950A (ja) 2016-10-13
EP3055309A1 (en) 2016-08-17
SI3055309T1 (sl) 2018-10-30
JP6411520B2 (ja) 2018-10-24
PT3055309T (pt) 2018-10-01
UY35774A (es) 2015-05-29
JO3442B1 (ar) 2019-10-20
US9751878B2 (en) 2017-09-05
US20150099777A1 (en) 2015-04-09
CY1121163T1 (el) 2020-05-29
CA2926544C (en) 2021-07-06
BR112016007620A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
AR097932A1 (es) Antagonista del receptor de somatostatina del subtipo 5 (sstr5)
AR106763A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR106605A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR100154A1 (es) Compuesto heterocíclico que contiene nitrógeno
ECSP15044389A (es) Compuesto peptídico
CO2019012271A2 (es) Péptido activador de receptor de gip
AR099995A1 (es) Piridilamidinas fungicidas
PE20151606A1 (es) DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
CL2015003491A1 (es) Compuestos químicos.
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
CO2018003367A2 (es) Benzamidas sustituidas con isoxazolina y análogos como insecticidas
AR097866A1 (es) Derivados de 4-azaindol
AR093825A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR128158A2 (es) Compuesto heterocíclico
AR089753A1 (es) Derivados de amida heterociclicos como antagonistas del receptor p2x7
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
AR095040A1 (es) Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina
AR089814A1 (es) Compuestos que modulan la actividad de los proteasomas
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida

Legal Events

Date Code Title Description
FG Grant, registration